Spyre Therapeutics Inc. research snapshot
SYRE AI stock analysis currently reads Spyre Therapeutics as a clinical-stage biotechnology company building a pipeline of antibody therapies for inflammatory bowel disease and rheumatic diseases, with no approved products or revenue. The central question is whether its anti-TL1A program (SPY002) can deliver best-in-class efficacy in Phase 2b/3 trials and whether the combination therapy strategy justifies the current $8.5 billion market cap. This page is an information tool, not investment advice.
Current price
$97.74
Market cap
$8.49 billion
AI score
35 / 100
Rating
Clinical-stage biotech with high uncertainty
Trend status
Strong uptrend over the past 52 weeks, momentum driven by Phase 2 catalysts
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Spyre is a pre-revenue biotech with no approved products. Its business quality depends entirely on pipeline execution. The anti-TL1A and anti-a4b7 programs target large markets, but commercial viability remains unproven. | Low |
| Moat | Pending any approved products or issued patents, the moat is minimal. If SPY002 or SPY003 succeed, potential moat from IP, formulation, and first-to-market advantage in novel combinations. Currently no revenue or product moat. | Low |
| Management | Management has experience in biotech development and capital raising. Strong cash position suggests disciplined financing. Insider stock sales reported in recent months raise some concern about conviction alignment. Split view. | Medium |
| Financial trend | No revenue. Q1 2026 net loss of roughly $69M, with TTM net loss of $148.7M. Cash burn rate supports operations into 2027-2028. Zero revenue makes standard financial trend analysis inapplicable. | High |
| Valuation | At $97.74, market cap $8.49B with negative P/E and negative FCF yield. Price/Book of 16.48x is high for a pre-revenue biotech. Valuation reflects optimism about pipeline potential, not current earnings power. | Medium |
| Technical trend | 52-week range $14.51 to $102.06. Stock has rallied approximately 580% from its 52-week low. Recent price near all-time highs. High beta of 3.02 suggests amplified moves. RSI may be overbought after the SPY002 catalyst run. | Medium-high |
| Risk level | Very high. Clinical-stage biotech binary risk. Cash burn, dilution, regulatory risk, competitive pipeline risk, insider selling, and high volatility. The stock could gap 40-80% on either positive or negative trial results. | High |
| AI confidence | Descriptive confidence is medium-high for basic financial data. Forward-return confidence is low because the stock is a binary clinical-stage biotech with high dependency on unread trial results. | Medium data confidence |
| Investment certainty | Low. The thesis hinges on clinical data readouts. A margin-of-safety approach would require deep biotech domain knowledge, which general AI analysis cannot replace. | Low |
SYRE AI stock forecast
The SYRE AI stock forecast should be read as a scenario range, not a precise prediction. EPS-based three-scenario analysis is not meaningful because Spyre has negative EPS with no revenue. The more useful framework compares pipeline probability of success, peak sales estimates for IBD therapies, cash runway, and comparable biotech valuations.
$150 to $200
More likely if SPY002 (anti-TL1A) delivers strong Phase 2b induction and maintenance data in ulcerative colitis and Crohn disease, if SPY003 (anti-IL-23) shows competitive efficacy, and if combination programs (SPY120, SPY130, SPY230) demonstrate additive benefits. Partnership or licensing deal with a large pharma would also support upside.
$80 to $120
More likely if SPY002 data prove adequate but not best-in-class, if SPY003 progresses without clear differentiation, and if the market prices in standard clinical-stage attrition risk. The stock trades within range of current levels with moderate volatility around data events.
$20 to $50
More likely if SPY002 fails to meet primary endpoints in Phase 2b, if safety concerns emerge, if cash burn forces dilutive financing, or if competing anti-TL1A programs from Roche/Genentech, Merck/Prometheus, or others demonstrate superiority.
SYRE AI technical analysis
SYRE technical analysis shows a strong uptrend from the $14.51 low over the past 52 weeks, driven largely by pipeline catalysts. The stock is trading near its all-time high of $102.06. High beta of 3.02 means the stock moves three times the market. Momentum is positive but extended. Volatility is elevated around clinical data events. Data cutoff: July 12, 2026.
| Level | Value | Why it matters |
|---|---|---|
| Resistance (all-time high) | $102.06 | 52-week high and potential psychological round-number resistance zone. |
| Support (near-term) | $88 - $94 | Recent consolidation zone after the SPY002 catalyst run. |
| Support (50-day MA) | $75 - $82 | Estimated 50-day moving average zone. May provide technical support on pullback. |
| Support (strong) | $50 - $60 | Pre-SPY002 catalyst levels. Would represent a significant technical breakdown. |
| RSI | Potentially overbought | After the strong run-up following positive Phase 2 results, RSI may be in overbought territory. |
| Volume | Above average on catalysts | Volume spikes during data releases. Average daily volume ~1.48M shares. |
| Beta | 3.02 | High beta. Stock tends to amplify market moves by 3x. |
SYRE AI trading strategy
The SYRE AI trading strategy provides frameworks for monitoring, not personalized advice. Clinical-stage biotech stocks require position sizing that accounts for binary event risk. Traders should focus on catalyst calendars, liquidity during data events, and gap-risk management.
Build a watchlist of key catalyst dates (Phase 2b data, regulatory milestones, DSMB reviews). Enter a small position 2-4 weeks before expected data, with a defined invalidation level below recent support. Take partial profits into strength after positive results. Be prepared for gaps in either direction on data day.
Position size should not exceed 2-5% of portfolio given binary risk. Use a hard stop below the last major support level or reduce to cash before high-impact data events.
If the stock is in a confirmed uptrend (price above both 50-day and 200-day MAs), consider buying on pullbacks to the 50-day MA or to identified support zones. Trail stops below the most recent swing low.
Trend-following in high-beta biotech requires wider stops. Monitor volume: declining volume on up-moves may signal trend exhaustion. Reduce exposure before catalyst events.
Investment research summary
Spyre Therapeutics is developing antibody therapies for inflammatory bowel disease (ulcerative colitis and Crohn disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). The company has no approved products or revenue. Its value depends entirely on pipeline success. The lead programs target the a4b7 integrin (SPY001), TL1A (SPY002/SPY072), and IL-23 (SPY003) pathways, including novel fixed-dose combinations.
No current product moat. Potential future moat drivers include: issued or pending patents for antibody sequences and combinations, first-mover advantage in fixed-dose combination biologics for IBD, and manufacturing know-how. These are unproven. Competitive risk is high: multiple large pharma companies (Roche, Merck, AbbVie, Johnson & Johnson) are developing IBD therapies, including competing anti-TL1A programs.
The most likely failure paths are: (1) SPY002 misses efficacy endpoints in Phase 2b, or shows inadequate differentiation versus competing anti-TL1A programs from Roche and Merck; (2) safety signals emerge from combination therapies involving dual immunosuppression; (3) cash burn forces dilutive secondary offering before value-creating milestones; (4) the renamed entity carries no legacy value from the Aeglea BioTherapeutics era.
The management team has relevant biotech experience. The cash position of $741M suggests prudent capital management. Insider stock sales reported in recent months warrant monitoring for conviction signals. The company successfully completed the reverse merger/rename from Aeglea BioTherapeutics. Capital allocation priorities will be tested as cash is deployed into pipeline expansion.
IBD is a large and growing market with significant unmet need. The global IBD therapeutics market is estimated at $15-20 billion annually and growing. Anti-TL1A has emerged as one of the most promising novel mechanisms in IBD, attracting significant interest from large pharma. Spyre competes in a hot space where multiple players have deep pockets. The combination therapy approach is novel but unproven in clinical settings.
At $8.49B market cap with no revenue, Spyre trades at a premium to many pre-commercial biotechs. Comparable analysis: Apogee Therapeutics (APGE) at $10B market cap with similar-stage pipeline, Immunovant (IMVT) at $8.1B. Spyre premium reflects enthusiasm for anti-TL1A data. Pre-commercial biotech pricing is inherently speculative, with valuation driven by peak sales estimates and probability-adjusted NPV models rather than traditional multiples.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current Price | $97.74 (close July 10), $97.81 (after hours) | Yahoo Finance | July 10, 2026 |
| Market Cap | $8.49 billion | Yahoo Finance, financial_rigor.py verification | July 10, 2026 |
| Enterprise Value | $7.90 billion | Yahoo Finance | July 10, 2026 |
| Shares Outstanding | ~86.84 million (calculated: $8.49B / $97.74) | Derived from market cap and price, financial_rigor.py verified | July 12, 2026 |
| EPS (TTM) | -$2.12 | Yahoo Finance | July 10, 2026 |
| Net Income (TTM) | -$148.7 million | Yahoo Finance | July 10, 2026 |
| Cash & Equivalents | $741.47 million | Yahoo Finance | July 10, 2026 |
| Free Cash Flow (TTM) | -$75.52 million | Yahoo Finance | July 10, 2026 |
| Price/Book | 16.48x | Yahoo Finance, financial_rigor.py verified | July 10, 2026 |
| Beta | 3.02 | Yahoo Finance | July 10, 2026 |
| 52-Week Range | $14.51 - $102.06 | Yahoo Finance | July 10, 2026 |
| Analyst Price Target | $101.53 avg ($78 low - $135 high) | Yahoo Finance, Deutsche Bank (Buy, PT $135) | June 23, 2026 |
| Employees | 112 | Yahoo Finance | July 10, 2026 |
This SYRE AI stock analysis page is an information tool, not investment advice. All data is sourced from publicly available information and verified using automated financial tools. The analysis uses scenario-based forecasting that relies on current data and assumptions that may change. Forecasts are not guarantees of future performance. Spyre Therapeutics is a clinical-stage biotechnology company with no approved products or revenue, making it a high-risk investment. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
